Treace Medical Concepts, Inc. Common Stock (TMCI) is a publicly traded Healthcare sector company. As of May 21, 2026, TMCI trades at $2.82 with a market cap of $178.40M and a P/E ratio of -2.93. TMCI moved +3.31% today. Year to date, TMCI is +6.82%; over the trailing twelve months it is -57.85%. Its 52-week range spans $1.17 to $10.79. Analyst consensus is neutral with an average price target of $3.56. Rallies surfaces TMCI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Treace Maintains 2026 Revenue Outlook Despite Q1 Sales Decline: Treace Medical Concepts reported a first-quarter revenue decline and maintained its full-year 2026 revenue outlook. Management highlighted that new product adoption is accelerating procedure volume growth, partially offsetting pricing and product mix headwinds.
| Metric | Value |
|---|---|
| Price | $2.82 |
| Market Cap | $178.40M |
| P/E Ratio | -2.93 |
| EPS | $-0.96 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.79 |
| 52-Week Low | $1.17 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $207.32M |
| Net Income | $-61.04M |
| Gross Margin | 79.72% |
4 analysts cover TMCI: 0 strong buy, 1 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $3.56.